Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 184

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Mining biomarkers in human sera using proteomic tools

Zhang, Rulin, Barker, Lisa, Pinchev, Deborah, Marshall, John, Rasamoelisolo, Michèle, Smith, Chris, Kupchak, Peter, Kireeva, Inga, Ingratta, Leslee, Jackowski, George·2004·PROTEOMICS

Abstract

One of the major difficulties in mining low abundance biomarkers from serum or plasma is due to the fact that a small number of proteins such as albumin, α2‐macroglobulin, transferrin, and immunoglobulins, may represent as much as 80% of the total serum protein. The large quantity of these proteins makes it difficult to identify low abundance proteins in serum using traditional 2‐dimensional electrophoresis. We recently used a combination of multidimensional liquid chromatography and gel electrophoresis coupled to matrix‐assisted laser desorption/ionization‐quadrupole‐time of flight and Ion Trap liquid chromatography‐tandem mass spectrometry to identify protein markers in sera of Alzheimer's disease (AD), insulin resistance/type‐2 diabetes (IR/D2), and congestive heart failure (CHF) patients. We identified 8 proteins that exhibit higher levels in control sera and 36 proteins that exhibit higher levels in disease sera. For example, haptoglobin and hemoglobin are elevated in sera of AD, IR/D2, and CHF patients. The levels of several other proteins including fibrinogen and its fragments, alpha 2‐macroglobulin, transthyretin, pro‐platelet basic protein, protease inhibitors clade A and C, as well as proteins involved in the classical complement pathway such as complement C3, C4, and C1 inhibitor, were found to differ between IR/D2 and control sera. The sera levels of proteins, such as the 10 kDa subunit of vitronectin, alpha 1‐acid glycoprotein, apolipoprotein B100, fragment of factor H, and histidine‐rich glycoprotein were observed to be different between AD and controls. The differences observed in these biomarker candidates were confirmed by Western blot and the enzyme‐linked immunosorbent assay. The biological meaning of the proteomic changes in the disease states and the potential use of these changes as diagnostic tools or for therapeutic intervention will be discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pmic.200300495

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 184

Metadata

Authors
Zhang, R., Barker, L., Pinchev, D., Marshall, J., Rasamoelisolo, M., Smith, C., Kupchak, P., Kireeva, I., Ingratta, L., & Jackowski, G.
Venue
PROTEOMICS
Publisher
Wiley
Published
2004-01
Volume
4
Issue
1
Pages
244-256
ISSN
  • 1615-9853 (ISSN-L)
  • 1615-9861
OpenAlex
W2076398846
Cited by
184
References
1
FWCI
5.19
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mining biomarkers in human sera using proteomic tools. https://app.cochat.ai/papers/10.1002/pmic.200300495
The paper
Zhang, R., Barker, L., Pinchev, D., Marshall, J., Rasamoelisolo, M., Smith, C., Kupchak, P., Kireeva, I., Ingratta, L., & Jackowski, G. (2004). Mining biomarkers in human sera using proteomic tools. PROTEOMICS. https://doi.org/10.1002/pmic.200300495

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.